| Target Validation Information | |||||
|---|---|---|---|---|---|
| TTD ID | T69991 | ||||
| Target Name | Wee1-like protein kinase (WEE1) | ||||
| Type of Target |
Clinical trial |
||||
| Drug Potency against Target | MK-1775 | Drug Info | IC50 = 5.2 nM | [2] | |
| 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione | Drug Info | IC50 = 97 nM | [1] | ||
| Action against Disease Model | MK-1775 | Drug Info | MK-1775. This compound inhibits phosphorylation of CDC2 at Tyr15 (CDC2Y15), a direct substrate of Wee1 kinase in cells. MK-1775 abrogates G(2) DNA damage checkpoint, leading to apoptosis in combination with DNA-damaging chemotherapeutic agents such as gemcitabine, carboplatin, and cisplatin selectively in p53-deficient cells. In vivo, MK-1775 potentiates t uMor growth inhibition by these agents, and cotreatment does not significantly increase toxicity. The enhancement of antit uMor effect by MK-1775 was well correlated with inhibition of CDC2Y15 phosphorylation in t uMortissue and skin hair follicles | [3] | |
| References | |||||
| REF 1 | Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors. Eur J Med Chem. 2009 Apr;44(4):1383-95. | ||||
| REF 2 | Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer. 2009 Jun 8;8:34. | ||||
| REF 3 | Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009 Nov;8(11):2992-3000. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.